178.32
Iqvia Holdings Inc stock is traded at $178.32, with a volume of 74,107.
It is up +0.39% in the last 24 hours and up +5.89% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$178.39
Open:
$179.39
24h Volume:
74,107
Relative Volume:
0.05
Market Cap:
$29.76B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
22.10
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
-3.85%
1M Performance:
+5.89%
6M Performance:
-19.22%
1Y Performance:
+12.45%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
178.29 | 29.77B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
474.26 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
182.15 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
570.50 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
130.94 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
|
WAT
Waters Corp
|
354.11 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
(IQV) Risk Channels and Responsive Allocation - Stock Traders Daily
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
IQVIA Holdings Stock (US46266C1053): Analyst Views and Valuation Under the Microscope - AD HOC NEWS
Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity - TradingView
Here's why IQVIA Holdings (IQV) is a strong momentum stock - MSN
More than 25 health leaders flag AI choke points from lab to patient - Stock Titan
IQVIA Holdings, Inc. (IQV) Stock Analysis: Exploring a Potential 25% Upside in Healthcare Innovation - DirectorsTalk Interviews
Is IQVIA Holdings stock outperforming the Dow? - MSN
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Is More Than a Contract Research Outsourcing Trade - AlphaStreet
IQVIA HOLDINGS INC CMNRo Khanna Congressional Trade on May. 27, 2026 - Quiver Quantitative
IQVIA Holdings Inc. Indenture and 8-K Filing Details for Notes Issuance (June 11, 2026) - Minichart
IQVIA Holdings Stock (US46266C1053): sector peers frame the valuation debate - AD HOC NEWS
IQVIA Holdings Inc. (IQV) Announces €950 Million Notes Offering - GuruFocus
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA Raises €950 Million Via 4.625% Senior Notes Due 2033 to Refinance Debt - TradingView
€950M 4.625% 2033 notes support IQVIA (NYSE: IQV) debt refinancing - Stock Titan
IQVIA (IQV) Q1 2026 Earnings Call Transcript - AOL.com
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IQVIA Holdings earnings preview: What to expect - MSN
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Q1 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment - Yahoo Finance UK
Is IQVIA Holdings Stock Outperforming the Dow? - Barchart.com
IQVIA Holdings Inc. $IQV Shares Sold by Marks Group Wealth Management Inc - MarketBeat
TD Cowen Adjusts Price Target on IQVIA to $233 From $213, Maintains Buy Rating - marketscreener.com
Los Angeles Capital Management LLC Grows Position in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings, Inc. (IQV) Stock Analysis: A 23.79% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Cantillon Capital Management LLC Boosts Stake in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Debt Refinance And EPS Upgrade Reshape Long Term Risk Profile - Yahoo Finance
Bank of New York Mellon Corp Lowers Position in IQVIA Holdings Inc. $IQV - MarketBeat
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
How IQVIA’s €950 Million Debt Refinancing and 2026 Outlook Update Will Impact IQVIA Holdings (IQV) Investors - Sahm
(IQV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Vaughan Nelson Mid Cap Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
IQVIA Holdings Prices €950 Million Senior Notes Offering - TipRanks
IQVIA prices €950M senior notes due 2033 at 4.625% - TradingView
€950M IQVIA (NYSE: IQV) senior notes due 2033 for refinancing debt - Stock Titan
IQVIA prices €950 million senior notes due 2033 By Investing.com - Investing.com Australia
IQVIA (IQV) Up 3.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
IQVIA prices €950 million senior notes due 2033 - Investing.com
IQVIA Announces Pricing of Senior Notes - Business Wire
IQVIA unit announces senior notes offering - MSN
Barclays upgrades IQVIA stock rating on scale, execution strength - Investing.com
IQVIA Holdings Inc. (IQV) Announces €950 Million Senior Notes Of - GuruFocus
HSBC Adjusts Price Target on IQVIA to $210 From $240, Maintains Buy Rating - Moomoo
IQVIA Announces €950 Million Senior Notes Offering - TipRanks
IQVIA to raise €950M via 2033 senior notes to refinance debt - TradingView
€950M IQVIA (NYSE: IQV) senior notes planned to refinance debt - Stock Titan
IQVIA Holdings Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
IQVIA Holdings (IQV) Plans €950M Senior Notes Offering for Debt Refinancing - GuruFocus
IQVIA Announces Offering of Senior Notes - 01net
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):